biib091
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2019 (NCT03943056)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06640933 | Phase 1 | Oct 16, 2024 | Biogen |
| NCT06574828 | Phase 1 | Aug 29, 2024 | Biogen |
| NCT06311786 | Phase 1 | Apr 8, 2024 | Biogen |
| NCT05798520 | Phase 2 | Jul 25, 2023 | Biogen |
| NCT04564612 | Phase 1 | Sep 28, 2020 | Biogen |
| NCT03943056 | Phase 1 | May 13, 2019 | Biogen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 6 | 6 | 2 | 2019 |
1 organizations
Page 1 / 1